Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia.

Onco Targets Ther · 2013 · PMC3594007 · PMID 23493838

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In addition, the incidence of on-treatment progression to accelerated phase or blast crisis was lower with bosutinib (2%, n = 4) compared with imatinib (4%, n = 10), but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.